WearOptimo

About WearOptimo

WearOptimo, established in 2018, is a company operating in the advanced medical technology sector with a focus on microwearable sensors. The firm was founded by Professor Mark Kendall, a biomedical engineer recognized for his previous work on the vaccine Nanopatch. His background in developing minimally invasive medical devices directly informs WearOptimo's core technology. The company's mission is to transition healthcare from a reactive to a proactive model, emphasizing early detection and intervention.

The core of WearOptimo's business is the development of small, flexible, and affordable skin-patch sensors. These devices are designed to continuously monitor critical biomarkers in the interstitial fluid, a layer just beneath the skin. This approach provides real-time, continuous data on a person's health status, aiming to offer insights that are currently only available through more invasive and infrequent blood tests. The technology is positioned to serve both individual health monitoring and clinical healthcare markets, providing data to patients and their physicians.

WearOptimo is developing a portfolio of sensors for various applications. One of the initial products focuses on hydration, aiming to provide early warnings for dehydration in athletes, industrial workers, and the elderly. Another significant area of development is a sensor for monitoring cardiac biomarkers, with the goal of detecting early signs of a heart attack. The business model appears to be centered on the development and sale of these single-use, affordable sensor patches. In 2023, the company initiated clinical trials for its first sensor, a key milestone in its product development lifecycle. WearOptimo has secured financial and strategic backing from entities including the Australian National University, Aspen Medical, and various government bodies, which supports its research, development, and manufacturing efforts.